Symptomatic treatment of multiple sclerosis using cannabinoids: Recent advances

Expert Review of Neurotherapeutics

Volumn 7, Issue 9, 2007, Pages 1157-1163

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoids; Multiple sclerosis; Pain; Spasticity

Indexed keywords

CANNABINOID DERIVATIVE; CANNABIS; DRONABINOL; NABILONE; TETRAHYDROCANNABINOL;

CHRONIC PAIN; CONSENSUS; FETUS DEVELOPMENT; HUMAN; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; REVIEW; SPASTICITY; TREMOR; URINARY TRACT INFECTION;

CANNABINOIDS; CLINICAL TRIALS; HUMANS; MENTAL DISORDERS; MULTIPLE SCLEROSIS; PAIN; PHYSICIAN'S PRACTICE PATTERNS;

EID: 34548821248     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.9.1157     Document Type: Review

References (64)

1. Consroe P, Musty R, Rein J et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44-48 (1997).
2. Woolridge E, Barton S, Samuel J et al. Cannabis use in HIV for pain and other medical symptoms. J. Pain Symptom Manage. 29, 358-368 (2005).
3. Smith PF. Sativex® (GW-1000). Curr. Opin. Investig. Drugs 5, 748-754 (2004).
4. Rice AS. Cannabinoids and pain. Curr. Opin. Investig. Drugs 2, 399-414 (2001).
5. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 63, 569-611 (2001).
6. Kreitzer AC, Regehr WG. Retrograde signalling by endocannabinoids. Curr. Opin. Neurobiol. 12, 324-330 (2002).
7. Alger BE. Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68, 247-286 (2002).
8. Ashton JC. Cannabinoids for the treatment of inflammation. Curr. Opin. Invest. Drugs 8, 373-384 (2007). •• Summarizes and evaluates the most recent evidence relating to cannabinoid (CB)2 receptors and inflammation.
9. Eljasschewitsch E, Witting A, Mawrin C et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67-79 (2006).
10. Achiron A, Miron S, Lavie V et al. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 102, 26-31 (2000).
11. Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302 (2001).
12. Baker D, Pryce G, Croxford JL et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87 (2000).
13. Berrendero F, Sanchez A, Cabranes A et al. Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41, 195-202 (2001).
14. Benito C, Romero JP, Tolon RM et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are aare specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 27(9), 2396-2402 (2007).
15. Campbell FA, Tramer MR, Carroll et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br. Med. J. 323, 13-16 (2001).
16. Tramer MR, Caroll D, Campbell FA et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Br. Med. J. 323, 16-21 (2001).
17. Notcutt W, Price M, Miller R et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59, 440-452 (2004).
18. Buggy DJ, Toogood L, Maric S et al. Lack of analgesic efficacy of oral Δ-9-tetrahydrocannabinol in post-operative pain. Pain 106,169-172 (2003). • Example of a negative effect of a cannabinoid on pain.
19. Attal N, Brasseur L, Guirimand D et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur. J. Pain 8,173-177 (2004). • Example of a negative effect of a cannabinoid on pain.
20. Naef M, Curatolo M, Petersen-Felix S et al. The analgesic effect or oral Δ-9-tetrahydrocannabinol (THC), morphine and a THC and morphine combination in healthy subjects under experimental pain conditions. Pain 105, 79-88 (2003). • Example of a negative effect of a cannabinoid on pain.
21. Killestein J, Hoogervorst ELJ, Reif M et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 58, 1404-1407 (2002).
22. Zajicek J, Fox P, Sanders H et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet 362, 1517-1526 (2003).
23. Zajicek JP, Sanders HP, Wright DE et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J. Neurol. Neurosurg. Psychiatr. 76, 1664-1669 (2005). •• Follow-up study of the Cannabinoids in Multiple Sclerosis (CAMS) trial.
24. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. Br. Med. J. 329, 253-261 (2004).
25. Wade DT, Robson P, House H et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17, 21-29 (2003).
26. Wade DT, Makela P, Robson P et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441 (2004).
27. Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 10, 417-424 (2004).
28. Rog DJ, Nurmikko TJ, Friede T et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65, 812-819 (2005). •• One of the most recent clinical trials of cannabinoid in multiple sclerosis (MS).
29. Blake DR, Robson P, Ho M et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex®) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50-52 (2006). •• Recently published study of the effects of cannabinoid on rheumatoid arthritis-related pain.
30. Wade DT, Makela PM, House H et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12, 639-645 (2006).
31. Colin C, Davies P, Mutiboko IK et al. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296 (2007). •• Recent report of the long-term effects of Cannabis-based medicines.
32. Fox P, Bain PG, Glickman S et al. The effects of cannabis on tremor in patients with multiple sclerosis. Neurology 62, 1105-1109 (2004).
33. Holdcroft A, Maze M, Dore C et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for post-operative pain management. Anesthesiology 104, 1040-1046 (2006). • Recent study of the effects of a Cannabis extract on postoperative pain.
34. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology 68, 515-521 (2007). •• Study of the effects of smoking Cannabis on pain related to HIV.
35. Kaarst M, Salim K, Burtsein S et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled study. JAMA 290, 1757-1762 (2003).
36. Wissel J, Haydn T, Muller J et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J. Neurol. 253, 1337-1341 (2006).
37. Brady CM, DasGupta R, Dalton C et al. An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10, 425-433 (2004).
38. Freeman RM, Adekanmi O, Waterfield MR et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic Floor Dysfunct. 17, 636-641 (2006).
39. Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Mult. Scler. 10, 339-340 (2004).
40. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD001332 (2000).
41. Chan GCK, Hinde TR, Impey S et al. Hippocampal neurotoxicity of Δ-9-tetrhydrocannabinol. J. Neurosci. 18, 5322-5332 (1998).
42. Nagayama T, Sinor AD, Chen J et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995 (1999).
43. McKallip RJ, Lombard C, Fisher M et al. Δ-9- tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Therap. 302, 451-465 (2002).
44. El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. 23, 149-156 (2004).
45. Abrams DI, Hilton JF, Leiser RJ et al. Short-term effects of cannabinoids in patients with HIV-1 infection. Ann. Intern. Med. 139, 258-266 (2003).
46. Beal JE, Olson R, Lefkowitz L et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome associated anorexia. J. Pain Symptom Manage. 14, 7-14 (1997).
47. Pope HG, Gruber AJ, Hudson JI et al. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiat. 58, 909-915 (2001).
48. Pope HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsychological effects of cannabis. Curr. Psych. Rep. 3, 507-512 (2001).
49. Jager G, Kahn RS, Van Den Brink W et al. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacol. (Berl.) 185, 358-368 (2006).
50. Fried PA, Watksinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 23, 421-430 (2001).
51. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol. Teratol. 23, 1-11 (2001).
52. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16 year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 25, 427-436 (2003).
53. Goldschmidt L, Richardson GA, Cornelius MD et al. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol. Teratol. 26, 521-532 (2004).
54. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol. Teratol. 22, 325-336 (2000).
55. Smith AM, Fried PA, Hogan MJ et al. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol. Teratol. 26, 533-542 (2004).
56. Degenhardt L, Tennant C, Gilmour S et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10 month prospective study. Psychol. Med. 37(7), 927-934 (2007). •• One of the most recent studies of the potential link between Cannabis use and psychosis.
57. Fergusson DM, Horwood J, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100, 354-366 (2005).
58. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis and psychotic symptoms in young people. Br. Med. J. 330, 11-16 (2005).
59. Rossler W, Riecher-Rossler A, Angst J et al. Psychotic experiences in the general population: a twenty year prospective community study. Schiz. Res. 92, 1-14 (2007). •• One of the most recent studies of the potential link between Cannabis use and psychosis.
60. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol. Psychiatry 57, 1117-1127 (2005).
61. Haney M, Ward AS, Comer SD et al. Abstinence symptoms following oral THC administration in humans. Psychopharmacol. (Berl.) 141, 385-404 (1999).
62. Haney M, Ward AS, Comer SD et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacol. (Berl.) 141, 395-404 (1999).
63. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97, 621-632 (2002).
64. Tanda G, Goldberg SR. Cannabinoids: reward, dependence and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacol. (Berl.) 169, 115-134 (2003).